Lunit Teams With Discovery Life Sciences on AI Pathology for Biopharma
Seoul – October 12, 2026 -- Lunit (KRX: 328130) has partnered with Discovery Life Sciences, a lab that supports more than 350 active clinical trial programs, to roll out the Lunit SCOPE suite across biopharmaceutical research.
The AI-powered pathology platform will run inside Discovery's biomarker and tissue analysis workflows. Both companies will tailor it to each client program's design, working directly with pharmaceutical and biotechnology customers.
Discovery brings 25 years of assay experience and 2,000 trial programs to the deal
Discovery has delivered biomarker services for more than 2,000 clinical trial programs. Its specialty laboratory services cover the drug development lifecycle end to end. The partners expect the combination of Discovery's global biospecimen network and Lunit's AI image analysis to broaden worldwide access to the SCOPE platform.